Otros idiomas Granules India Limited

Acciones

GRANULES

INE101D01020

Farmacéuticos

Diferido Bombay S.E. Otros sitios de cotización 10:48:32 18/06/2026			Variación 5 días	Varia. 1 de enero.
760,95 ^INR	+2,67 %		-1,14 %	+26,05 %

12/06	GRANULES INDIA LIMITED : El Sushil Financial Services continua con un recomendación de compra	ZM
01/05	GRANULES INDIA LIMITED : Choice Equity Broking reitera su recomendación de compra	ZM

Otros idiomas

29/04	Granules India : Q4FY26 Revenue from operations at INR 14,706 Mn up 23% YoY, EBITDA at INR 3,521 Mn up 40% YoY, PBT before Exceptional Item at INR 2,464 Mn up 48% YoY, PAT at INR 2,016 Mn up 33% YoY.
29/04	Granules India Q4 consol profit 2.02 billion rupees
29/04	Granules India Limited Recommends Final Dividend for the Financial Year 2025-2026
29/04	Granules India's fourth-quarter profit jumps on strong demand
29/04	Granules India Limited Designates Mr. Harsha Chigurupati as Senior Management Personnel, Effective April 30, 2026
29/04	Granules India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026
09/04	Indian drugmaker Granules to tighten oversight after US FDA warning, exec says
31/03	Granules receives VAI classification after US FDA inspection
05/03	Granules India : Packaging Facility in US gets FDA EIR with No Action Indicated Status
05/03	Granules India Arm Gets "No Action Indicated" Status from US FDA for Viginia Unit; Shares Up 3%
05/03	Granules says packaging facility in US gets FDA EIR with No Action Indicated status
24/02	Granules India: Analysts Bet on Continued Upside
23/02	Granules India Limited announced that it has received INR 6.656249925 billion in funding
28/01	Granules India : SERP Join Handsto Strengthen Breast Cancer Screening in Sangareddy
23/01	Granules India quarterly profit jumps on strong demand in North America, Europe
23/01	Granules Dec-quarter Consol Profit 1.50 Billion Rupees
23/01	Granules India : Q3FY26 Revenue from operations at INR 13,879 Mn up 22% YoY, EBITDA at INR 3,081 Mn up 34% YoY, PBT at INR 2,022 Mn up 32% YoY, PAT at INR 1,502 Mn up 28% YoY.
23/01	Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025
08/01	Granules India : Pharmaceuticals, Inc. Receives FDA Tentative Approval with 180-Day Exclusivity for Generic Amphetamine Extended-Release Tablets (gDYANAVEL XR)
08/01	Granules India Arm Gets US FDA's Tentative Nod for Amphetamine Extended-Release Tablets
08/01	Granules unit receives FDA tentative approval for generic amphetamine with 180-day exclusivity
05/01	Sigachi Industries Appoints Chief People Officer
23/12	Granules India Limited announced that it expects to receive INR 6.656249925 billion in funding
23/12	Granules India Approves the Proposals to Raise an Aggregate INR 17,625.0 Million Through the Preferential Issuance of Convertible Warrants and Equity Shares
23/12	Granules to issue warrants up to 14.63 billion rupees